Literature DB >> 15315836

Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif.

Oscar Bruna-Romero1, Carolina D Rocha, Moriya Tsuji, Ricardo T Gazzinelli.   

Abstract

A major malaria vaccine candidate, the circumsporozoite (CS) protein of Plasmodium, is a pre-erythrocytic stage antigen that is attached to the surface of the sporozoites through a glycosylphosphatidylinositol (GPI) anchor. However, here we show that the motif that signals for glycosylphosphatidylinositol anchor addition interferes with the immunogenicity of this protein and reduces protection in mice upon immunization with a recombinant adenovirus. The presence of the glycosylphosphatidylinositol-anchoring motif sequentially affected total circumsporozoite protein production, cellular distribution, antigen processing and secretion, leading to less effective antigen presentation. Consistently, vaccination with an adenovirus recombinant carrying the anchoring motif-disrupted circumsporozoite gene, resulted in significant increase of the number of interferon-gamma (IFN-gamma) producing T cells and specific IgG2a isotype antibodies, ensuing more effective vaccination. Given that the anchoring motif is highly conserved among different species of Plasmodium, anti-malaria subunit vaccines encoded by recombinant vectors that aim at the induction of strong cellular immunity could maximize immunogenicity by removing anchoring motifs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315836     DOI: 10.1016/j.vaccine.2004.03.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.

Authors:  Michael Walther; Fiona M Thompson; Susanna Dunachie; Sheila Keating; Stephen Todryk; Tamara Berthoud; Laura Andrews; Rikke F Andersen; Anne Moore; Sarah C Gilbert; Ian Poulton; Filip Dubovsky; Eveline Tierney; Simon Correa; Angela Huntcooke; Geoffrey Butcher; Jack Williams; Robert E Sinden; Adrian V S Hill
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

3.  Cell wall glycolipids from Corynebacterium pseudotuberculosis strains with different virulences differ in terms of composition and immune recognition.

Authors:  Miriam Flores Rebouças; Dan Loureiro; Thiago Doria Barral; Nubia Seyffert; José Tadeu Raynal; Thiago Jesus Sousa; Henrique Cesar Pereira Figueiredo; Vasco Azevedo; Roberto Meyer; Ricardo Wagner Portela
Journal:  Braz J Microbiol       Date:  2020-07-25       Impact factor: 2.476

4.  Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.

Authors:  Hong-Duck Kim; Kazuki Tahara; J Adam Maxwell; Robert Lalonde; Tatsuya Fukuiwa; Kohtaro Fujihashi; Kent R Van Kampen; Fan-Kun Kong; De-chu C Tang; Ken-ichiro Fukuchi
Journal:  J Gene Med       Date:  2007-02       Impact factor: 4.565

Review 5.  Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Authors:  Javier E Garcia; Alvaro Puentes; Manuel E Patarroyo
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

7.  Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Authors:  V Ann Stewart; Shannon M McGrath; Patrice M Dubois; Maria G Pau; Pascal Mettens; Joseph Shott; Michelle Cobb; J Robert Burge; David Larson; Lisa A Ware; Marie-Ange Demoitie; Gerrit Jan Weverling; Babak Bayat; Jerome H H V Custers; Marie-Claude Dubois; Joe Cohen; Jaap Goudsmit; D Gray Heppner
Journal:  Infect Immun       Date:  2007-02-16       Impact factor: 3.441

8.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

9.  A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.

Authors:  Joanna Kubler-Kielb; Fathy Majadly; Zuzana Biesova; Christopher P Mocca; Chunyan Guo; Ruth Nussenzweig; Victor Nussenzweig; Satish Mishra; Yimin Wu; Louis H Miller; Jerry M Keith; Teh-Yung Liu; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

10.  Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.

Authors:  Jinfei Yu; Bo Li; Xiaorui Chen; Jingcai Lu; Dandan Wang; Tiejun Gu; Wei Kong; Yongge Wu
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.